Mitral valve replacement the patient on cardiopulmonary bypass. In a study of 99 patients who had mitral valve surgery for regurgitation from January 1990 to June 1996, overall mortality was 4%, which included 3 operative deaths and 4 late deaths. Overall 5-year survival rate was 92%. With mitral valve replacement surgery, there are risks such as bleeding, infection or reaction to anesthesia. Risks depend on a patient’s age, general condition, specific medical conditions, and heart function. Neuropsychological and psychopathologic changes following mitral valve replacement surgery have been recognized from the very beginning of modern heart surgery. Variables correlated with nonpsychotic mental disorder after
Mitral valve replacement biological or mechanical valve. The left artium is then closed, and the patient weaned from cardiopulmonary bypass. After surgery patients are typically taken to an intensive care unit (ICU). There are two primary types of artificial mitral valves: mechanical valves and bioprosthetic tissue (biological) valves. The mechanical valves are made from metal and pyrolytic carbon, and can last a lifetime. Patients with mechanical valves must take blood-thinning medications to prevent clotting. Bioprosthetic valves are made from animal tissues. Use of these biological valves allows patients to avoid blood thinners. However, the bioprosthetic valves may only last 10 to 15 years.